Matches in SemOpenAlex for { <https://semopenalex.org/work/W1992339833> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W1992339833 endingPage "198" @default.
- W1992339833 startingPage "190" @default.
- W1992339833 abstract "Two randomized, open-label clinical studies involving healthy female volunteers aged 18–45 years (study 1, N = 32; study 2, N = 40) are described, which characterize the pharmacokinetics and steady-state dosage regimen performance of 2 novel, modified-release tranexamic acid tablet formulations. The objective of these studies was to identify the optimum product formulation to advance into late-phase clinical trials for heavy menstrual bleeding. For study 1, participants received single 1.3-g doses (2 650-mg tablets) of tranexamic acid modified-immediate-release (MIR) and tranexamic acid delayed-release (DR) formulations under fasting conditions compared with nonfasting conditions (after breakfast). For study 2, participants received tranexamic acid MIR or tranexamic acid DR as a single 1.3-g dose followed by a dosage regimen of 1.3 g every 8 hours for 5 days. Plasma tranexamic acid concentrations reached minimum effective levels (≥5 μg/mL) within 1.5 hours and within 3 hours after a 1.3-g tranexamic acid MIR and tranexamic acid DR dose, respectively. Food did not appreciably influence tranexamic acid MIR pharmacokinetics, whereas a high-fat meal significantly lowered the maximum concentration produced with tranexamic acid DR. Peak systemic exposure and maintenance of plasma tranexamic acid concentrations within the therapeutic range (5–15 μg/mL) were optimally achieved with 1.3 g of the MIR formulation dosed every 8 hours. The MIR and DR formulations were well tolerated. Peak-to-trough steady-state performance of the tranexamic acid MIR 1.3-g product (dosed every 8 hours, or 3 times daily, for up to 5 days) supported its advancement to late-phase clinical trials in women with heavy menstrual bleeding." @default.
- W1992339833 created "2016-06-24" @default.
- W1992339833 creator A5008637837 @default.
- W1992339833 creator A5012496878 @default.
- W1992339833 creator A5040484071 @default.
- W1992339833 creator A5066487380 @default.
- W1992339833 creator A5087660192 @default.
- W1992339833 date "2012-05-01" @default.
- W1992339833 modified "2023-09-24" @default.
- W1992339833 title "Pharmacokinetic Studies in Women of 2 Novel Oral Formulations of Tranexamic Acid Therapy for Heavy Menstrual Bleeding" @default.
- W1992339833 cites W1993653149 @default.
- W1992339833 cites W1995103763 @default.
- W1992339833 cites W1999546242 @default.
- W1992339833 cites W2001022087 @default.
- W1992339833 cites W2018289814 @default.
- W1992339833 cites W2021738675 @default.
- W1992339833 cites W2032960682 @default.
- W1992339833 cites W2036468563 @default.
- W1992339833 cites W2076652047 @default.
- W1992339833 cites W2091692603 @default.
- W1992339833 cites W2095465279 @default.
- W1992339833 cites W2103865819 @default.
- W1992339833 cites W2107648329 @default.
- W1992339833 cites W2120216515 @default.
- W1992339833 doi "https://doi.org/10.1097/mjt.0b013e318205427a" @default.
- W1992339833 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21248612" @default.
- W1992339833 hasPublicationYear "2012" @default.
- W1992339833 type Work @default.
- W1992339833 sameAs 1992339833 @default.
- W1992339833 citedByCount "13" @default.
- W1992339833 countsByYear W19923398332012 @default.
- W1992339833 countsByYear W19923398332013 @default.
- W1992339833 countsByYear W19923398332016 @default.
- W1992339833 countsByYear W19923398332019 @default.
- W1992339833 countsByYear W19923398332020 @default.
- W1992339833 countsByYear W19923398332021 @default.
- W1992339833 crossrefType "journal-article" @default.
- W1992339833 hasAuthorship W1992339833A5008637837 @default.
- W1992339833 hasAuthorship W1992339833A5012496878 @default.
- W1992339833 hasAuthorship W1992339833A5040484071 @default.
- W1992339833 hasAuthorship W1992339833A5066487380 @default.
- W1992339833 hasAuthorship W1992339833A5087660192 @default.
- W1992339833 hasConcept C112705442 @default.
- W1992339833 hasConcept C141071460 @default.
- W1992339833 hasConcept C2779637338 @default.
- W1992339833 hasConcept C2781413609 @default.
- W1992339833 hasConcept C2991743468 @default.
- W1992339833 hasConcept C42219234 @default.
- W1992339833 hasConcept C71924100 @default.
- W1992339833 hasConcept C98274493 @default.
- W1992339833 hasConceptScore W1992339833C112705442 @default.
- W1992339833 hasConceptScore W1992339833C141071460 @default.
- W1992339833 hasConceptScore W1992339833C2779637338 @default.
- W1992339833 hasConceptScore W1992339833C2781413609 @default.
- W1992339833 hasConceptScore W1992339833C2991743468 @default.
- W1992339833 hasConceptScore W1992339833C42219234 @default.
- W1992339833 hasConceptScore W1992339833C71924100 @default.
- W1992339833 hasConceptScore W1992339833C98274493 @default.
- W1992339833 hasIssue "3" @default.
- W1992339833 hasLocation W19923398331 @default.
- W1992339833 hasLocation W19923398332 @default.
- W1992339833 hasOpenAccess W1992339833 @default.
- W1992339833 hasPrimaryLocation W19923398331 @default.
- W1992339833 hasRelatedWork W1979403001 @default.
- W1992339833 hasRelatedWork W2205554088 @default.
- W1992339833 hasRelatedWork W2315138922 @default.
- W1992339833 hasRelatedWork W2317612395 @default.
- W1992339833 hasRelatedWork W2328659429 @default.
- W1992339833 hasRelatedWork W2800022962 @default.
- W1992339833 hasRelatedWork W2883682937 @default.
- W1992339833 hasRelatedWork W3009399736 @default.
- W1992339833 hasRelatedWork W3086340038 @default.
- W1992339833 hasRelatedWork W3174346913 @default.
- W1992339833 hasVolume "19" @default.
- W1992339833 isParatext "false" @default.
- W1992339833 isRetracted "false" @default.
- W1992339833 magId "1992339833" @default.
- W1992339833 workType "article" @default.